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Poster Session II 119important second parameter to define patients at risk for EBV-
PTLDwhomight be candidates for preemptive interventions.Total
number of 49 papers and 19 conference abstracts were available.
Most reports included only a small number of patients. Overall re-
sponse rateswere: 61% (14/23 pts) for prophylactic use of rituximab;
88% (214/243 pts) for preemptive therapy with rituximab, and 72%
(56/77 pts) for rituximab used for therapy of EBV-PTLD disease.
Rituximab was safe and well tolerated.Conclusions: Since a signif-
icant proportion of patients died from PTLD in spite of rituximab
treatment, and since availability of EBV-CTLs is limited, it is rea-
sonable to recommend preemptive treatment with rituximab for in-
creasing EBV-DNA-emia. Emerging problem might be related to
down-regulation of CD20 expression on PTLD cells following re-
peated therapy, causing refractoriness to rituximab treatment due to
lack of CD20 expression. Further studies are needed to confirm the
efficacy of these treatment strategies.323
CHRONIC GRAFT VERSUS HOST DISEASE AND PRETRANSPLANT DIS-
EASE STATUS PREDICT OUTCOMES IN PATIENTS WITH HEMATOLOGIC
MALIGNANCIES UNDERGOING REDUCED INTENSITY ALLOGENEIC
STEM CELL TRANSPLANTATION
Shah, M., Agha, M., Mapara, M., Lenhart, K., Raptis, A. University of
Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine,
Pittsburgh, PA.
Reduced intensity stem cell transplantation (SCT) is an effective
treatmentmodality for patients with hematologicmalignancies who
are not candidates for conventional myeloablative SCT. We con-
ducted a retrospective review of all patients with hematologicmalig-
nancies receiving a reduced intensity allogeneic SCT from July
2002 to July 2007. Data pertaining to patient demographics, en-
graftment, disease status pre/post transplant, graft versus host dis-
ease (GVHD), and HLA matching was analyzed to identify
factors significantly affecting the clinical outcome.
73 patients, with a median age of 55 (range of 19–70) and with the
diagnoses of ALL (n5 8), AML (n5 30), CLL (n5 3), CML (n5
1), Hodgkins (n 5 7), non-Hodgkins (n 5 7), MDS (n 5 11), and
MM (n5 6) underwent a reduced intensity SCT using a fludarabine
based conditioning regimen. Median and mean follow-up times
were 5.6 and 9.9 months respectively. 39 (53%) received unrelated
donor grafts and 34 (47%) received sibling donor grafts. 56 patients
(77%) received fully matched grafts whereas 17 patients (23%) had
an antigen or allele mismatch. Neither of those variables affected
clinical outcome. Median time to neutrophil recovery was 15 days
(range of 9–41) and median time to platelet recovery was 18 days
(range of 9–42). Graft failure was observed in 6 of the 73 patients.
Median overall survival and disease free survival for all patients
was 7.7 and 6.6 months. Median overall survival for patients with
persistent disease or in remission at the time of the SCT was 5.6
and 21.8 months (p 5 0.01) while that for disease free survival was
5.7 and 8.4 months (p 5 0.06). Median overall survival with and
without chronicGVHDwas 25.6 and 9.4months (p\0.0001) while
median disease free survival was 18.2 and 6.0 months (p\ 0.0001).
Patients with limited chronic GVHD have not yet reached median
overall survival while median disease free survival was 18.4 months.
Those with extensive chronic GVHD had medians of 9.2 months
for both overall and disease free survival (p 5 0.004 and p 5 0.02).
Reduced intensity SCT is an effective treatment modality in pa-
tients with hematologic malignancies, though it is most effective in
patients who are in remission at the time of transplant and should be
offered in this setting. Patients with limited chronic GVHD had
a better outcome suggesting the presence of potent anti-tumor ac-
tivity of the donor immune competent cells without the detrimental
effects in clinical outcome caused by extensive chronic GVHD.324
THE FEASIBILITY OF USING CCR5D32/D32 HEMATOPOIETIC STEM CELL
TRANSPLANTS FOR IMMUNE RECONSTITUTION IN HIV-INFECTED CHIL-
DREN
Chen, T.K.1, Moore, T.B.2, Territo, M.3, Chow, R.4, Tonai, R.4,
Petz, L.4, Rossi, J.5, Mitsuyasu, R.3, Rosenthal, J.6, Forman, S.6,Zaia, J.A.5, Bryson, Y.J.1. 1David Geffen School of Medicine at
UCLA, Los Angeles, CA; 2David Geffen School of Medicine at UCLA,
Los Angeles, CA; 3David Geffen School of Medicine at UCLA, Los An-
geles, CA; 4StemCyte, Inc., Covina, CA; 5Beckman Research Institute
of City of Hope, Duarte, CA; 6Beckman Research Institute of City of
Hope, Duarte, CA.
Despite treatment with highly-active antiretroviral therapy
(HAART), someHIV infected patients fail to reconstitute their im-
mune functions and are intolerant to side effects of long term
HAART, indicating the need to develop novel immune-based ther-
apies. Hematopoietic stem cells (HSC) have been used to reconsti-
tute the immune system in patients with primary
immunodeficiencies, genetic diseases, and childhood cancers.
Transplantation for HIV infection has been attempted, but re-in-
fection of the grafted cells is a concern. Studies demonstrate that ho-
mozygosity for a 32 bp deletion in the HIV-1 CCR5 co-receptor
gene (CCR5D32) is associated with protection against R5 HIV in-
fection, while CCR5D32 heterozygosity is associated with slower
disease progression. Thus, T-cells developing after a transplant
withHSC homozygous for the CCR5D32mutation should be resis-
tant to R5 HIV infection. The CCR5D32 allele is found in Cauca-
sian populations with 1% being homozygous and 15–20%
heterozygous. We have shown that the HIV coreceptor tropism
may revert from X4 to R5 under the pressure of HAART. In addi-
tion, we and others have found that the replication competent virus
recovered fromCD4T-cells reservoirs in children are R5.We eval-
uated the feasibility of HSC transplantation using CCR5D32/D32
stem cells for the immune reconstitution of HIV-infected children
who are immunocompromised despite HAART. StemCyte, an in-
ternational cord blood bank, has been actively screening their
cord blood units (CBUs) for the CCR5D32 allele. To date, Stem-
Cyte has identified 30 homozygotes and 754 heterozygotes for the
CCR5D32 mutation among 10,488 CBUs screened. 44 patients
were randomly selected from our cohort of HIV-infected children
and adolescents. HLA typing was performed to identify patients
with potential HLA matched CBUs. Initial statistical consider-
ations demonstrated that 100–150 patients would need to be
screened in order to identify 2–4 potential HLA matched CBUs.
We found 7 (15.9%) of our patients with a 4/6 HLA match to the
identified homozygous CBUs, and 20 (45.4%) of our patients that
are a 3/6 match to the identified homozygous CBUs. 2 of 7 patients
with an identified 4/6 HLA match continue to have detectable
plasma viremia despite HAART. 2 of 7 patients have cords with suf-
ficient cell count for transplant. Thus, we identified and character-
ized 7 potential HIV-positive patients who could benefit from
a transplant ofHLA-matched, CCR5D32/D32 umbilical cord blood
stem cells.HLAmatched (4 out of 6) patients and homozygous CCR5D32 cord blood
units
Patient Cord Blood UnitAge GenderWeight
(kg) GenderVolume
(mL)TNC/kg
(107)
CD34/kg
(105)
Mismatched
loci17 years M 70.1M 95.0 0.61 0.18 BM 64.68 0.81 0.26 B, DRB1F 64.20 1.07 0.18 B, DRB1M 67.00 1.50 0.21 A, DRB111 years M 41.3F 64.20 1.82 0.30 A, B5 years M 23.2M 64.68 2.46 0.78 A, B25 years M 60.9F 152.20 5.77 2.17 B, DRB124 years M 70.4M 64.29 0.97 0.14 A, DRB111 years F 42.6F 63.80 1.55 0.31 A, B22 months M 12.7F 64.20 5.92 0.97 A, B
